Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma
DOI:10.3969/j.issn.1001-5256.2020.10.035
- VernacularTitle:肝细胞癌的靶向及免疫治疗进展
- Author:
Jianying WEI
1
;
Wei SUN
;
Xiaomin LIU
;
Jinglong CHEN
Author Information
1. Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
molecular targeted therapy;
immunotherapy
- From:
Journal of Clinical Hepatology
2020;36(10):2320-2324
- CountryChina
- Language:Chinese
-
Abstract:
There are still high incidence and mortality rates of hepatocellular carcinoma at present, and systemic treatment plays an important role in the treatment of advanced hepatocellular carcinoma. This article describes the application of molecular-targeted drugs and immune checkpoint inhibitors in hepatocellular carcinoma and points out that dual-targeted therapy, dual immunotherapy, and targeted therapy combined with immunotherapy are the current research hotspots in the treatment of hepatocellular carcinoma.
